Jane Street Group LLC Has $1.17 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

Jane Street Group LLC raised its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 33.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 142,014 shares of the company’s stock after buying an additional 35,472 shares during the quarter. Jane Street Group LLC owned 0.11% of Wave Life Sciences worth $1,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in WVE. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Wave Life Sciences by 23.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock valued at $37,000 after acquiring an additional 856 shares in the last quarter. Profund Advisors LLC bought a new position in shares of Wave Life Sciences in the second quarter valued at approximately $53,000. Principal Financial Group Inc. acquired a new stake in shares of Wave Life Sciences in the second quarter worth $74,000. Mackenzie Financial Corp boosted its holdings in shares of Wave Life Sciences by 13.6% during the 2nd quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock worth $79,000 after buying an additional 1,905 shares during the period. Finally, Point72 DIFC Ltd acquired a new position in Wave Life Sciences in the 3rd quarter valued at $98,000. 89.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Wave Life Sciences in a report on Wednesday, November 13th. StockNews.com downgraded shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 13th. Royal Bank of Canada increased their price target on shares of Wave Life Sciences from $7.00 to $15.00 and gave the stock a “sector perform” rating in a research report on Monday, October 21st. B. Riley lifted their price objective on Wave Life Sciences from $19.00 to $22.00 and gave the company a “buy” rating in a report on Monday, November 4th. Finally, Wells Fargo & Company increased their target price on shares of Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Wave Life Sciences has an average rating of “Moderate Buy” and a consensus target price of $22.22.

Insider Buying and Selling at Wave Life Sciences

In related news, CEO Paul Bolno sold 50,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $15.00, for a total value of $750,000.00. Following the transaction, the chief executive officer now owns 217,351 shares in the company, valued at approximately $3,260,265. This represents a 18.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Chris Francis sold 36,000 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $576,000.00. The disclosure for this sale can be found here. Insiders sold a total of 436,544 shares of company stock worth $6,271,569 over the last ninety days. 29.10% of the stock is currently owned by corporate insiders.

Wave Life Sciences Stock Performance

NASDAQ WVE opened at $12.90 on Monday. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of -11.62 and a beta of -1.21. Wave Life Sciences Ltd. has a 52 week low of $3.50 and a 52 week high of $16.74. The stock’s 50 day moving average price is $14.41 and its two-hundred day moving average price is $9.27.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.